ESSA Pharma Inc. (EPIX) News
Filter EPIX News Items
EPIX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
EPIX News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest EPIX News From Around the Web
Below are the latest news stories about ESSA PHARMA INC that investors may wish to consider to help them evaluate EPIX as an investment opportunity.
3 Promising US Penny Stocks With Market Caps Under $80MAs 2024 concludes, the U.S. stock market has experienced a mix of highs and lows, with major indices posting strong annual gains despite a weak finish. In the current market landscape, penny stocks—often representing smaller or newer companies—continue to capture investor interest due to their potential for value and growth. While the term "penny stocks" may seem outdated, these investments can still offer compelling opportunities for those looking beyond large-cap names, especially when... |
When Will ESSA Pharma Inc. (NASDAQ:EPIX) Turn A Profit?We feel now is a pretty good time to analyse ESSA Pharma Inc.'s ( NASDAQ:EPIX ) business as it appears the company may... |
ESSA Pharma: Fiscal Q4 Earnings SnapshotThe Vancouver, British Columbia-based company said it had a loss of 14 cents per share. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 19 cents per share. |
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company that, prior to the discontinuation of its clinical trials and preclinical and other development programs, has been focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fourth quarter and fiscal year ended September 30, 2024. |
ESSA Pharma And 2 Other US Penny Stocks To WatchAs the U.S. stock market reaches record highs amid an election-fueled rally, investors are increasingly exploring diverse opportunities to capitalize on this momentum. Penny stocks, often seen as a relic of past trading days, still hold significant potential for growth and value discovery in today's market landscape. These smaller or newer companies can offer a mix of affordability and upside potential when backed by strong financials, presenting an underappreciated avenue for investors... |
ESSA Pharma downgraded by Oppenheimer, Piper Sandler after drug setback in trialsESSA Pharma (NASDAQ:EPIX), a biotechnology company focused on developing treatments for metastatic castration-resistant prostate cancer, saw its stock downgraded by major brokerages Oppenheimer and Piper Sandler after the company said it was halting development of its lead drug candidate, masofaniten. This decision followed a futility analysis during a Phase II clinical trial, where masofaniten, combined with the existing anti-cancer drug enzalutamide, was being evaluated against enzalutamide alone. |
Sector Update: Health Care Stocks Rise Late AfternoonSector Update: Health Care Stocks Rise Late Afternoon |
Top Midday DeclinersTop Midday Decliners |
ESSA Pharma halts Phase II study of masofaniten in prostate cancer treatmentA futility analysis of the study suggested a low probability of achieving the prespecified primary endpoint. |
ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate CancerESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it has made the decision to terminate the Phase 2 clinical trial evaluating in a 2:1 randomization masofaniten combined with enzalutamide versus enzalutamide single agent in patients with metastatic castration-resistant prostate cancer ("mCRPC") naïve to second-generation antiandrogens. This decision, |